Results 151 to 160 of about 820 (178)

Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer. [PDF]

BMC Med
Hillmann J, Maass N, Bauerschlag DO, Flörkemeier I.   +3 more
europepmc   +1 more source

Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Annette M. Vogl, Saskia Schmitt, Isabelle Mai, Paul Machui, Sarah Herterich, Natascia Leonardi, Philipp Cyprys, Danila Hauswald, Philipp Ochtrop, Izabela Kozlowska, Annabel Kitowski, Marcus Gerlach, Florian Waldmann, Olivier Marcq, Pamela A. Trail, Dominik Schumacher, Günter R. Fingerle-Rowson, Björn Hock, Marc‐André Kasper, Jonas Helma   +19 more
openalex   +1 more source

Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Annette M. Vogl, Saskia Schmitt, Isabelle Mai, Paul Machui, Sarah Herterich, Natascia Leonardi, Philipp Cyprys, Danila Hauswald, Philipp Ochtrop, Izabela Kozlowska, Annabel Kitowski, Marcus Gerlach, Florian Waldmann, Olivier Marcq, Pamela A. Trail, Dominik Schumacher, Günter R. Fingerle-Rowson, Björn Hock, Marc‐André Kasper, Jonas Helma   +19 more
openalex   +1 more source

Characterization of Synthesized Ramucirumab-vcMMAE as a Potential Therapeutic Approach in Ovarian Cancer. [PDF]

ACS Omega
Erdogan D, Ayar Kayali H.
europepmc   +1 more source

Maternal loss of 24-hydroxylase causes increased intestinal calcium absorption and hypercalcemia during pregnancy but reduced skeletal resorption during lactation in mice. [PDF]

J Bone Miner Res
Maekawa AS, Bennin D, Hartery SA, Kirby BJ, Poulton IJ, St-Arnaud R, Sims NA, Kovacs CS.   +7 more
europepmc   +1 more source

The Vedotin Antibody-Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles. [PDF]

Mol Cancer Ther
Neff-LaFord HD, Carratt SA, Carosino C, Everds N, Cardinal KA, Duniho S, Schutten MM, Frantz C, Zuch de Zafra C, Harstad EB.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort

Clinical Lung Cancer, 2022
NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumors including breast, thyroid, ovarian and non-small cell lung cancer.
S Heynemann, H Yu, L Churilov, G Rivalland, K Asadi, R Mosher, F Hirsch, C Rivard, P Mitchell   +8 more
openaire   +2 more sources

Development of potent non-acylhydrazone inhibitors of intestinal sodium-dependent phosphate transport protein 2b (NaPi2b)

Bioorganic & Medicinal Chemistry, 2022
Inhibition of intestinal sodium-dependent phosphate transport protein 2b (NaPi2b), responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia. Previously, we aimed to identify new drugs for hyperphosphatemia treatment and obtained zwitterionic ...
Michihiro, Maemoto, Yuuki, Hirata, Shintaro, Hosoe, Jun, Ouchi, Masako, Uchii, Hidenori, Takada, Emi, Akizawa, Arata, Yanagisawa, Satoshi, Shuto   +8 more
openaire   +2 more sources

Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC).

Journal of Clinical Oncology, 2023
5545 Background: Biomarker driven therapies are increasingly being used for gynecologic cancers, with mirvetuximab soravtansine, a Folate Receptor alpha (FRa) targeting antibody drug conjugate (ADC) being a recent FDA approved agent for patients with FRa positive PROC. Uptifitamab rilsodotin (UpRi) is a late-stage, first in class NaPi2b-targeting ADC
Debra L. Richardson, Minal A. Barve, Erika P. Hamilton, Sara Kristina Taylor, Charles K Anderson, Joseph Buscema, Marilyn Huang, Rebecca Christian Arend, John L. Hays, Premal H. Thaker, Nehal J. Lakhani, Rebecca Mosher, Pamela Shaw, Chelsea Bradshaw, Min Lu   +14 more
openaire   +1 more source